MediStem Laboratories, Inc. MDSM Archives - Page 3 of 4

ThursdayMar 15, 2007 7:30 am

Medistem Laboratories, Inc. (MDSM) Outlines Progress Made in 2006

Medistem Laboratories, Inc. (MDSM) reported recently that 2006 was a very good year, in many respects. Its Chief Financial Officer, Steve Rivers noted that, "During 2006, we have built the necessary infrastructure to poise ourselves for future growth. We raised sufficient capital to finance the construction of our first licensee clinic and we ended the year with cash and cash equivalents of $986,000." He continued, "With revenue generating activities firmly underway, we reduced our cash used in operating activities to less than $100,000 in the fourth quarter of 2006. We are excited and motivated by not only our future business…

MondayFeb 26, 2007 12:47 pm

Medistem Laboratories, Inc. (MDSM) Sees the Immense Promise of Stem Cell Therapies

The founder of Medistem Laboratories, Inc., Neil Riordan was one who identified, very early, the immense promise of stem cell therapies. From that origin, the company's proprietary patent pending stem cell technology was born. The Company continues to gain a solid foothold in the Industry. MDSM has been executing its business model through the establishment of international clinics and forging key cooperative relationships with leading academic institutions. Through licensure of its trade secrets, know-how, and intellectual property, Medistem expects to generate millions in revenue while developing various drug candidates for the U.S marketplace. Let us hear your thoughts below:

ThursdayFeb 22, 2007 12:20 pm

Scientists from Medistem Laboratories Inc. (MDSM) See Broader Application for Stem Cells without the Use of Immune Suppression

Scientists from Medistem laboratories, Inc. (MDSM) have published a peer reviewed paper outlining the practical rationale for a broader medical use of cord stem cells, without the limiting feature of immune suppression. This concept for cord blood transplants, opens the door to an increasing number of potential medical applications, including Medistem's Angiostem platform, now under development for U.S. commercialization. Let us hear your thoughts below:

ThursdayFeb 08, 2007 1:22 pm

Medistem Laboratories Inc. (MDSM) Takes Major Step as it Launches Pre-Clinical Vascular Research

Medistem Laboratories, Inc. (MDSM) is launching, in cooperation with the Indiana University School of Medicine, pre-clinical research into its proprietary platform product known as AngioStem(TM) for the potential treatment of critical limb ischemia. This is a major leap forward for the Company, in its quest to ultimately be in a position, at a future point, to commence FDA trials in the US. The Company feels this is the first technology with potential to allow widespread use of cord blood transplants for generation of new blood vessels in a wide patent population base. Let us hear your thoughts below:

FridayFeb 02, 2007 9:53 am

Medistem Laboratories, Inc. (MDSM) Benefits from its Visionary Team of Healthcare Practitioners, Researchers, and Scientists

Medistem Laboratories, Inc. (MDSM) has a solid Management Team. Neil Riordan, PH.D., its Chairman, President, and Chief Executive has a broad management background with healthcare companies, coupled with extensive experience implementing medical protocols and treatments. He holds ten patents and has four patents pending. Roger Nocera, M.D., its Executive Vice President and Chief Medical Officer has had a successful career as a physician and scientist. He is medical director and owner of the Nocera Antiaging Clinic in Scottsdale, AZ. In addition, he founded and remains the medical director of MRI and CT at Arcadia Radiology & Open MRI, Ltd. in…

ThursdayFeb 01, 2007 11:28 am

Medistem Laboratories, Inc. (MDSM) Sees Potential Partnerships with Big Pharmaceutical Firms as a Win-Win Situation

As Medistem Laboratories, Inc. (MDSM) creates shareholder value with new Intellectual Property and treatment protocols; forging ongoing profitable business relationships with large pharmaceutical firms may well prove to be the ultimate victory. Data from its licenses will enhance its ability to produce positive clinical trial data. Data that can truly benefit the large firms while making MDSM a valued development partner. Let us hear your thoughts below:

WednesdayJan 31, 2007 3:28 pm

The Positioning of Intellectual Property Portfolios Represent Key Potential Revenue Streams for Biotech Firms like Medistem Laboratories, Inc. (MDSM)

The skillful management of a biotech patent portfolio is a key business component for success. Patent applications can be used defensively to protect ones own business operations or offensively to target other market segments, where the patent could later reap licensing royalty rewards. Medistem has a robust patent application portfolio spanning conditions from cancer and heart disease to tumors and lower back pain. Let us hear your thoughts below:

TuesdayJan 30, 2007 9:44 am

Medistem (MDSM) Scientists Develop Hypothesis Using an Already Clinically Approved Drug in the Treatment of Chronic Myeloid Leukemia

Medistem Laboratories, Inc. (MDSM) announced today that its scientists have co-authored a paper proposing a new leukemia treatment. In the Journal of Translational Medicine, the paper titled "Therapeutic use of Aldara in Chronic Myeloid Leukemia" is aimed to spur scientific interest in the connection between stem cells and the immune system. Let us hear your thoughts below:

TuesdayJan 30, 2007 8:42 am

Adult Stem Cell Therapies Offer Proven Scientific Results and Opportunity for Medistem Laboratories, Inc. (MDSM)

Adult stem cells, void of ethical issues, appear as useful as those derived from fetal or embryonic tissues. Research has shown that conditions ranging from heart disease, to peripheral vascular disease, and to neurological conditions; have achieved clinical improvement with stem cell treatment. This new frontier of medicine offers a clear opportunity for Medistem Laboratories, Inc.(MDSM). Let us hear your thoughts below:

MondayJan 29, 2007 10:23 am

Medistem Laboratories, Inc. (MDSM) Sees Huge Worldwide Market Potential for Stem Cell Research and Treatment

It is estimated that the stem cell industry could produce billions of dollars of revenues per year upon gaining approvals by the U.S. FDA. Globally, as safety and effectiveness have been demonstrated, many clinicians utilize stem cell therapy outside of the United States. Medistem (MDSM), is licenseing international medical facilities, to enable safe and standardized stem cell therapies. Let us hear your thoughts below:

Site Search

Company Search

Tag: MediStem Laboratories, Inc. MDSM